Marshall Wace LLP Sells 218,500 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Marshall Wace LLP reduced its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 76.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 67,457 shares of the medical instruments supplier’s stock after selling 218,500 shares during the quarter. Marshall Wace LLP owned approximately 0.17% of AngioDynamics worth $408,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ANGO. AE Wealth Management LLC purchased a new position in shares of AngioDynamics in the second quarter valued at about $87,000. State Board of Administration of Florida Retirement System increased its holdings in AngioDynamics by 44.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 4,780 shares during the period. Bayesian Capital Management LP purchased a new position in AngioDynamics during the 1st quarter valued at about $106,000. Concurrent Investment Advisors LLC raised its position in AngioDynamics by 152.2% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 29,503 shares of the medical instruments supplier’s stock valued at $178,000 after purchasing an additional 17,803 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in AngioDynamics by 9.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock worth $199,000 after buying an additional 2,821 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ANGO shares. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research note on Friday, October 4th. Canaccord Genuity Group decreased their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday, October 4th.

Insider Buying and Selling at AngioDynamics

In related news, CEO James C. Clemmer purchased 20,000 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were purchased at an average cost of $6.03 per share, with a total value of $120,600.00. Following the transaction, the chief executive officer now directly owns 681,582 shares in the company, valued at $4,109,939.46. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders acquired 22,568 shares of company stock valued at $135,847. Corporate insiders own 5.10% of the company’s stock.

AngioDynamics Stock Performance

ANGO stock opened at $6.14 on Friday. The company has a market capitalization of $245.94 million, a price-to-earnings ratio of -1.27 and a beta of 0.65. The business’s 50 day moving average price is $7.34 and its two-hundred day moving average price is $6.64. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The company had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. The firm’s revenue for the quarter was down 14.2% on a year-over-year basis. Sell-side analysts forecast that AngioDynamics, Inc. will post -0.41 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.